Results 61 to 70 of about 231 (96)

Somatrogon for growth hormone deficiency.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Somatrogon: First Approval

Drugs, 2022
Somatrogon (NGENLA®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients. Administered as a once-weekly subcutaneous injection, somatrogon reduces treatment burden relative to once-daily human growth hormone
Yvette N Lamb, Lamb Yvette N
exaly   +3 more sources